Skip to main content
Figure 4 | BMC Cancer

Figure 4

From: Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice

Figure 4

Systemic treatment of mice with subcutaneous tumors with PSCA-CAR-engineered T cells leads to delayed tumor growth and prolonged survival. Nude NMRI mice were injected subcutaneously with 3 × 106 mel526(PSCA) cells. One, seven and fourteen days later the mice received intravenous injection of 1 × 107 PSCA-CAR-transduced T cells (CAR T) or Mock-transduced T cells (Mock T). Twelve mice per group were used and tumor volumes were measured by caliper every second day. One experiment out of two is presented. (A) Tumor volume for individual mice treated with CAR T cells (n = 12). (B) Tumor volume for individual mice treated with Mock T cells (n = 12). (C) Pooled data on tumor volume for PSCA-CAR T cell-treated and Mock T cell-treated mice shows significant difference in tumor volume (p < 0.01, paired t-test). (D) Kaplan-Meier survival analysis shows significant difference in survival for mice treated with PSCA-CAR T cells and Mock T cells (p < 0.01, log rank test).

Back to article page
\